Pulse Biosciences Inc, a novel bioelectric medicine company progressing Nano-Pulse Stimulation (NPS) technology, announces that three clinical studies demonstrating positive results across its dermatologic portfolio are available via webcast at the virtual annual conference of the American Society for Laser Medicine and Surgery (ASLMS).
The virtual meeting went live on the ASLMS website on June 30, 2020. The clinical studies span the Company’s investigational use of NPS non-thermal energy in Nodular Basal Cell Carcinoma (BCC), Sebaceous Hyperplasia (SH) Lesions and Cutaneous Non-Genital Warts, along with e-Posters on pre-clinical observations of the effect of NPS energy on Murine Melanoma and Liver Tumors in situ.
“The robust body of clinical evidence demonstrated in the studies featured at the ASLMS virtual meeting outline the broad functional benefits of Nano-Pulse Stimulation technology in aesthetic and therapeutic dermatology. These results help to advance our goal of bringing a potentially paradigm-changing procedure to patients wishing to improve the health and appearance of their skin. We are especially grateful to our renowned scientific investigators for their research and for seamlessly adapting to a virtual presentation platform to highlight their important findings. We applaud the ASLMS for hosting an outstanding online educational event of this magnitude amid the COVID-19 pandemic.”
— Darrin Uecker, President and Chief Executive Officer of Pulse Biosciences
Dr E. Victor Ross, Director of the Laser and Cosmetic Dermatology Center at Scripps Clinic in San Diego, Calif, discusses interim results of an expanded study of Nano-Pulse Stimulation technology for treating cutaneous, non-genital warts. According to Dr Ross, this pivotal clinical study included additional sites, an increased number of subjects and the treatment of warts across more anatomic areas, which enabled broader use of NPS to treat this difficult group of skin lesions.
“Our interim findings of 87 treated warts on 27 patients showed improved efficacy with respect to high clearance ratings and no recurrence at 60 days after the last NPS treatment. Interestingly, NPS technology was particularly effective in clearing warts on the knees, hands, and legs. Furthermore, no plume was reported in a sub-cohort of patient treatments, as confirmed by a particulate counter. This could be a major advantage over thermal modalities that produce a plume of vapor or smoke that can contain contaminated debris particles since protecting the health and safety of our patients is always our top concern.”
— Dr E. Victor Ross
Smoke or vapor plume is the byproduct of thermal-based procedures to treat skin tissue and can carry debris particles containing dust, chemicals, and infectious matter. While the use of ventilation systems, safe clinical practices and personal protective equipment are used, the absence of plume using NPS technology may provide an important additional benefit.
ASLMS VIRTUAL PRESENTATIONS
Members of ASLMS may access these presentations through the ASLMS Online Learning Center.
[Source: Pulse Biosciences]
ASDSA and ASLMS Partner to Develop Guidance for Cosmetic Dermatology Practices During COVID-19
Nano-Pulse Stimulation Technology Platform Demonstrates Positive Results